Impel NeuroPharma Inc. (IMPL) Announces FDA Approval of TRUDHESA for Migraine
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Impel NeuroPharma Inc. (IMPL) Launches 3M Share Proposed Offering
September 7, 2021 4:01 PM EDTImpel NeuroPharma, Inc. (NASDAQ: IMPL) announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock. All of the shares of common stock are being offered by Impel. In addition, Impel intends to grant the underwriters a 30-day option to... More
Impel Neuropharma (IMPL) PT Raised to $55 at Cowen on FDA Approval
September 3, 2021 10:57 AM EDTCowen analyst Ken Cacciatore raised the price target on Impel Neuropharma (NASDAQ: IMPL) to $55.00 (from $35.00) while maintaining an Outperform rating.
The analyst commented, "The FDA has approved Trudhesa for the treatment of acute migraines with a clean label right in line with our... More
Impel NeuroPharma Inc. (IMPL) surges 59% as trading reumes on FDA approval
September 3, 2021 9:18 AM EDTImpel NeuroPharma Inc. (NASDAQ: IMPL) surges 59% as trading reumes on FDA approval
... More